Corcept Faces New Competitive Pressure as Genmab’s Rina-S Shows Broad Benefit in Platinum-Resistant Ovarian Cancer

Rina-S shows significant PFS and OS gains in platinum-resistant ovarian cancer, challenging Corcept’s Lifyorli position.